Roivant Sciences Q4 2023 Earnings Report $11.13 -0.24 (-2.11%) As of 01/31/2025 04:00 PM Eastern Earnings HistoryForecast Roivant Sciences EPS ResultsActual EPS-$0.20Consensus EPS -$0.41Beat/MissBeat by +$0.21One Year Ago EPSN/ARoivant Sciences Revenue ResultsActual Revenue$27.38 millionExpected Revenue$18.94 millionBeat/MissBeat by +$8.44 millionYoY Revenue GrowthN/ARoivant Sciences Announcement DetailsQuarterQ4 2023Date6/28/2023TimeN/AROIV Upcoming EarningsRoivant Sciences will be holding an earnings conference call on Monday, February 10 at 8:00 AM Eastern. Interested parties can register for or listen to the call. Conference Call ResourcesSlide DeckPress ReleaseROIV Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Roivant Sciences Earnings HeadlinesBrokerages Set Roivant Sciences Ltd. (NASDAQ:ROIV) Target Price at $17.93January 31 at 1:49 AM | americanbankingnews.comRoivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025January 29 at 4:16 PM | globenewswire.comTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intelligence sector. But here's the thing …February 1, 2025 | Weiss Ratings (Ad)Roivant Sciences : le président Eric Venker vend des actions pour 1,13 million de dollarsJanuary 23, 2025 | fr.investing.comRoivant Sciences augmente sa participation dans Immunovant avec un achat de 336,9 millions de dollarsJanuary 16, 2025 | fr.investing.comRoivant Sciences buys Immunovant Inc. shares and repurchases its own stock for $336.9 million eachJanuary 16, 2025 | finance.yahoo.comSee More Roivant Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Roivant Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Roivant Sciences and other key companies, straight to your email. Email Address About Roivant SciencesRoivant Sciences (NASDAQ:ROIV), a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.View Roivant Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings PayPal (2/3/2025)Palantir Technologies (2/3/2025)NXP Semiconductors (2/3/2025)Mitsubishi UFJ Financial Group (2/3/2025)Mondelez International (2/4/2025)Advanced Micro Devices (2/4/2025)Alphabet (2/4/2025)Alphabet (2/4/2025)Amgen (2/4/2025)Banco Bilbao Vizcaya Argentaria (2/4/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
